News

Zepbound trims more belly fat than Wegovy, study shows
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Novo Nordisk's CEO Ousted: Deep-Value Opportunity With Sentiment Risks
Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...
Novo Nordisk, U.S. biotech company team up to create obesity pills
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
Fierce Biotech2d
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...
Novo Nordisk Stock: Seems Like A No-Brainer At These Levels
Discover why Novo Nordisk A/S' undervalued shares present a buying opportunity, with strong sales growth, profitability, and ...
Here’s how much extra weight is lost with Zepbound over Wegovy
A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...